Tonix Pharmaceuticals Holding C (TNXP) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Tonix Pharmaceuticals Holding C

NasdaqGS•Healthcare•Biotechnology

$13.14-0.23(-0.02%)Market closed

Market Cap

$189.97M

P/S

6.5x

P/B

0.9x

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

How this company scores

AverageMetricSide Score: 48/100

Strongest: Growth (18/25); weakest: Cash & Earnings Quality (6/25).

Profitability9/25

Growth18/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Growing revenueInterest easily coveredNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 6.5x5y range 2.6x – 5072.0x

Currently below its 12-quarter median.

P/B · 0.9x5y range 0.2x – 126117.3x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $189.97M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $29.10M
Q. Revenue: $13.54M
TTM EBITDA: $-162.36M
TTM Op. Income: $-165.43M
Q. Op. Income: $-42.53M
TTM Net Income: $-159.67M
Q. Net Income: $-40.55M
EPS: $-2.44
Shares Out.: $16.64M

$29.10M in TTM revenue grew 196.0% YoY, reaching $13.54M last quarter. TTM EBITDA of $-162.36M and TTM operating income of $-165.43M show growth is flowing through to the bottom line. However, net income is negative at $159.67M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 4 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -309.5%
Op. Margin: -314.1%
Net Margin: -299.4%

Op. margin of -314.1% is up 1102.2% YoY — cost efficiency is improving. Net margin at -299.4% Across the last 8 quarters, operating margin has risen for 4 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 6.5x
P/B Ratio: 0.9x

P/S of 6.5x and P/B of 0.9x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $254.09M
Cash: $176.23M
Long-Term Debt: N/A
Book Value: $222.28M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-42.24M
TTM Free Cash Flow: $-158.11M
FCF Margin: -543.3%
FCF / Net Income: 1.0

TTM FCF of $-158.11M on $-42.24M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 5 consecutive quarters — a weakening trend.